Asthma treatment in the 21st century: what's next? (Q35998622)

11 August 2017

1 reference

title

Asthma treatment in the 21st century: what's next? (English)

1 reference

11 August 2017

1 reference

Stephen P Peters

1

1 reference

11 August 2017

1 December 2004

1 reference

Clinical Reviews in Allergy & Immunology

11 August 2017

1 reference

11 August 2017

27

1 reference

11 August 2017

3

1 reference

11 August 2017

197-205

1 reference

https://scigraph.springernature.com/pub.10.1385/criai:27:3:197

11 August 2017

0 references

cites work

Personalised prescribing for asthma--is pharmacogenetics the answer?

1 reference

12 December 2020

Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma

1 reference

12 December 2020

Serious asthma exacerbations in asthmatics treated with high-dose formoterol

1 reference

12 December 2020

Heterogeneity of therapeutic responses in asthma

1 reference

12 December 2020

Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma

1 reference

12 December 2020

Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group

1 reference

12 December 2020

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism

1 reference

12 December 2020

Inheritance and drug response

1 reference

12 December 2020

Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription

1 reference

12 December 2020

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

1 reference

12 December 2020

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor

1 reference

12 December 2020

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

1 reference

12 December 2020

Pharmacogenetics of Asthma

1 reference

12 December 2020

Treatment of asthma with drugs modifying the leukotriene pathway.

1 reference

12 December 2020

The beta-agonist dilemma

1 reference

12 December 2020

Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature

1 reference

12 December 2020

Pharmacogenetics in the laboratory and the clinic.

1 reference

12 December 2020

Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

1 reference

12 December 2020

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

12 December 2020

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

12 December 2020

Case-control study of salmeterol and near-fatal attacks of asthma

1 reference

12 December 2020

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

12 December 2020

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

1 reference

12 December 2020

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

1 reference

12 December 2020

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

1 reference

12 December 2020

Pharmacogenetics and the future of medical practice

1 reference

12 December 2020

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

1 reference

12 December 2020

Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Anti-immunoglobulin E (omalizumab) therapy in allergic asthma

1 reference

12 December 2020

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

1 reference

12 December 2020

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group

1 reference

12 December 2020

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

1 reference

12 December 2020

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

12 December 2020

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

1 reference

12 December 2020

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

12 December 2020

The trials and tribulations of IL-5, eosinophils, and allergic asthma

1 reference

12 December 2020

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group

1 reference

12 December 2020

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

12 December 2020

The next generation of PDE4 inhibitors

1 reference

12 December 2020

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

1 reference

12 December 2020

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

12 December 2020

Theophylline and PDE4 inhibitors in asthma.

1 reference

12 December 2020

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

1 reference

12 December 2020

Significant variability in response to inhaled corticosteroids for persistent asthma

1 reference

12 December 2020

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial

1 reference

12 December 2020

Potential masking effects of salmeterol on airway inflammation in asthma

1 reference

12 December 2020

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network

1 reference

12 December 2020

Targeting cytokines in asthma therapy: round one.

1 reference

12 December 2020

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

1 reference

12 December 2020

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

12 December 2020

Phosphodiesterase 4 inhibitors for the treatment of COPD.

1 reference

12 December 2020

Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing.

1 reference

12 December 2020

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

12 December 2020

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

12 December 2020

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

1 reference

12 December 2020

New directions in allergic diseases: mechanism-based anti-inflammatory therapies

1 reference

12 December 2020

Genomics and medicine: distraction, incremental progress, or the dawn of a new age?

1 reference

12 December 2020

Identifiers

DOI

10.1385/CRIAI:27:3:197

1 reference

PubMed ID

15630156

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15630156